AGNPF.US Algernon Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
0.2600 USD
Close of Nov 13, 2026
0.2183 0.6400
Market cap
USD 2.51M
P/E
-
P/B
3.16x
ROE
-136.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.

Is AGNPF.US undervalued?

Graham number

The Graham number of Algernon Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Algernon Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Algernon Pharmaceuticals Inc yet.

Algernon Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Algernon Pharmaceuticals Inc

Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada, the United States, and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was for…

Full company profile